OCT1 Variants Linked to Metformin Clearance and Gluconeogenesis in Youth-Onset Type 2 Diabetes

Youth-onset type 2 diabetes (T2D) presents unique challenges, often progressing more aggressively than adult-onset forms and requiring effective, personalized treatment strategies. Metformin is a cornerstone therapy for T2D, primarily by reducing hepatic gluconeogenesis and improving insulin sensitivity. However, individual responses to metformin vary significantly, partly due to genetic factors influencing its pharmacokinetics. The organic cation transporter 1 (OCT1, encoded by SLC22A1) is a crucial transporter responsible for metformin uptake into hepatocytes, making OCT1 genetic variants key determinants of drug efficacy and safety.

The MIGHTY Study investigated the association between OCT1 genetic variants and parameters related to metformin clearance and gluconeogenesis in individuals with youth-onset type 2 diabetes. While the study's design focused on mechanistic insights, specific details regarding participant numbers, metformin dosing regimens, study duration, or the exact assays (qPCR, ELISA, etc.) used to measure clearance or gluconeogenesis were not provided in the abstract.

The study identified associations between specific OCT1 variants and both metformin clearance and gluconeogenesis. These mechanistic insights suggest that genetic variations in OCT1 play a role in how metformin is processed and its impact on glucose metabolism. However, the abstract does not provide specific quantitative results such as percentages, p-values, or fold-changes to detail the magnitude of these associations.